glp 1 stock price Moby | The GLP-1 wars are heating up. Novo Nordisk (NVO) is suing rival Eli Lilly (LLY), alleging the drugmaker used outdated clinical trial data The Rising Tide of GLP-1

Federal and state regulators have identified compounded GLP-1 advertising specifically as a category of concern

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen , Novo Nordisk, Prevention Bio, among others

All three have filed lawsuits that blame the popular class of weight-loss drugs known as GLP-1 receptor agonists, which include Ozempic, Wegovy and Mounjaro, and theyre part of a growing number of lawsuits alleging the drugs makers failed to sufficiently warn of the risk of certain severe injuries

A Phase 3 trial funded by the VA Office of Research and Development began enrolling in 2026 with primary completion estimated April 2028

Many Medicare Advantage plans include built-in Part D prescription drug coverage

The actual settlement amounts will depend heavily on bellwether trial outcomes and the strength of causation evidence presented by medical experts